$15.18
Insights on Bausch + Lomb Corp.
Revenue is down for the last 2 quarters, 1.17B → 1.09B (in $), with an average decrease of 6.3% per quarter
Netprofit is down for the last 2 quarters, -54.0M → -167.0M (in $), with an average decrease of 209.3% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 27.2% return, outperforming this stock by 43.6%
0.2%
Downside
Day's Volatility :2.26%
Upside
2.06%
13.31%
Downside
52 Weeks Volatility :40.05%
Upside
30.84%
Period | Bausch + Lomb Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.95% | -0.2% | 0.0% |
6 Months | 0.4% | 9.7% | 0.0% |
1 Year | -17.59% | 10.6% | 0.0% |
3 Years | -24.1% | 18.5% | -22.6% |
Market Capitalization | 5.4B |
Book Value | $18.95 |
Earnings Per Share (EPS) | -0.96 |
PEG Ratio | 4.87 |
Wall Street Target Price | 25.94 |
Profit Margin | -7.81% |
Operating Margin TTM | 1.37% |
Return On Assets TTM | 1.08% |
Return On Equity TTM | -4.69% |
Revenue TTM | 4.3B |
Revenue Per Share TTM | 12.3 |
Quarterly Revenue Growth YOY | 18.0% |
Gross Profit TTM | 2.2B |
EBITDA | 613.0M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | -0.89 |
EPS Estimate Current Year | 0.86 |
EPS Estimate Next Year | 1.2 |
EPS Estimate Current Quarter | 0.07 |
EPS Estimate Next Quarter | 0.2 |
What analysts predicted
Upside of 70.88%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | - |
Net Income | 710.0M | - |
Net Profit Margin | 19.37% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 3.08% |
Net Income | 298.0M | ↓ 58.03% |
Net Profit Margin | 7.89% | ↓ 11.48% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↓ 9.69% |
Net Income | -17.0M | ↓ 105.7% |
Net Profit Margin | -0.5% | ↓ 8.39% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 10.35% |
Net Income | 182.0M | ↓ 1170.59% |
Net Profit Margin | 4.83% | ↑ 5.33% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.8B | ↑ 0.08% |
Net Income | 15.0M | ↓ 91.76% |
Net Profit Margin | 0.4% | ↓ 4.43% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.1B | ↑ 10.03% |
Net Income | -260.0M | ↓ 1833.33% |
Net Profit Margin | -6.27% | ↓ 6.67% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 996.0M | ↑ 5.73% |
Net Income | -1000.0K | ↓ 93.33% |
Net Profit Margin | -0.1% | ↑ 1.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 931.0M | ↓ 6.53% |
Net Income | -88.0M | ↑ 8700.0% |
Net Profit Margin | -9.45% | ↓ 9.35% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 11.17% |
Net Income | -32.0M | ↓ 63.64% |
Net Profit Margin | -3.09% | ↑ 6.36% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 2.71% |
Net Income | -84.0M | ↑ 162.5% |
Net Profit Margin | -8.34% | ↓ 5.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 16.48% |
Net Income | -54.0M | ↓ 35.71% |
Net Profit Margin | -4.6% | ↑ 3.74% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 6.31% |
Net Income | -167.0M | ↑ 209.26% |
Net Profit Margin | -15.2% | ↓ 10.6% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | - |
Total Liabilities | 1.4B | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.3B | ↓ 1.76% |
Total Liabilities | 1.3B | ↓ 11.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↓ 3.93% |
Total Liabilities | 1.4B | ↑ 11.19% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 11.1B | ↑ 2.97% |
Total Liabilities | 4.0B | ↑ 184.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 13.4B | ↑ 20.62% |
Total Liabilities | 6.5B | ↑ 61.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.1B | ↑ 4.19% |
Total Liabilities | 4.0B | ↑ 3.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.2B | ↑ 0.22% |
Total Liabilities | 4.1B | ↑ 1.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.3B | ↑ 1.31% |
Total Liabilities | 4.3B | ↑ 4.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.1B | ↑ 15.49% |
Total Liabilities | 6.2B | ↑ 44.34% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.4B | ↑ 2.86% |
Total Liabilities | 6.5B | ↑ 5.45% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 13.3B | ↓ 1.11% |
Total Liabilities | 6.6B | ↑ 0.64% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 763.0M | - |
Investing Cash Flow | -74.0M | - |
Financing Cash Flow | -665.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 799.0M | ↑ 4.72% |
Investing Cash Flow | -186.0M | ↑ 151.35% |
Financing Cash Flow | -606.0M | ↓ 8.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 522.0M | ↓ 34.67% |
Investing Cash Flow | -256.0M | ↑ 37.63% |
Financing Cash Flow | -232.0M | ↓ 61.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 873.0M | ↑ 67.24% |
Investing Cash Flow | -214.0M | ↓ 16.41% |
Financing Cash Flow | -712.0M | ↑ 206.9% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 345.0M | ↓ 60.48% |
Investing Cash Flow | -215.0M | ↑ 0.47% |
Financing Cash Flow | 81.0M | ↓ 111.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 159.0M | ↑ 488.89% |
Investing Cash Flow | -90.0M | ↑ 83.67% |
Financing Cash Flow | -7.0M | ↓ 93.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -56.0M | ↓ 135.22% |
Investing Cash Flow | -64.0M | ↓ 28.89% |
Financing Cash Flow | 91.0M | ↓ 1400.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.0M | ↓ 57.14% |
Investing Cash Flow | -28.0M | ↓ 56.25% |
Financing Cash Flow | 90.0M | ↓ 1.1% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 48.0M | ↓ 300.0% |
Investing Cash Flow | -1.9B | ↑ 6621.43% |
Financing Cash Flow | 1.8B | ↑ 1912.22% |
Sell
Neutral
Buy
Bausch + Lomb Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bausch + Lomb Corp. | 5.12% | 0.4% | -17.59% | -24.1% | -24.1% |
Intuitive Surgical, Inc. | 6.15% | 29.51% | 28.07% | 45.72% | 151.48% |
Resmed Inc. | -4.4% | 28.39% | -6.63% | 1.01% | 81.81% |
Becton, Dickinson And Company | 0.96% | 2.24% | -5.96% | -0.3% | -0.22% |
West Pharmaceutical Services Inc | -10.32% | -6.31% | -4.27% | -1.41% | 182.66% |
Alcon Ag | 11.48% | 24.36% | 13.04% | 28.28% | 52.81% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bausch + Lomb Corp. | 914.0 | NA | 4.87 | 0.86 | -0.05 | 0.01 | NA | 18.95 |
Intuitive Surgical, Inc. | 72.45 | 72.45 | 7.13 | 6.29 | 0.16 | 0.08 | NA | 39.37 |
Resmed Inc. | 32.26 | 32.26 | 1.75 | 7.73 | 0.22 | 0.12 | 0.01 | 31.52 |
Becton, Dickinson And Company | 49.78 | 49.78 | 1.34 | 13.05 | 0.05 | 0.03 | 0.02 | 88.74 |
West Pharmaceutical Services Inc | 43.66 | 43.66 | 6.72 | 7.76 | 0.21 | 0.11 | 0.0 | 36.72 |
Alcon Ag | 42.24 | 42.24 | 4.59 | 3.07 | 0.05 | 0.02 | 0.0 | 42.13 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bausch + Lomb Corp. | Buy | $5.4B | -24.1% | 914.0 | -7.81% |
Intuitive Surgical, Inc. | Buy | $142.6B | 151.48% | 72.45 | 27.16% |
Resmed Inc. | Buy | $30.8B | 81.81% | 32.26 | 20.91% |
Becton, Dickinson And Company | Buy | $67.0B | -0.22% | 49.78 | 6.76% |
West Pharmaceutical Services Inc | Buy | $24.3B | 182.66% | 43.66 | 19.42% |
Alcon Ag | Buy | $44.0B | 52.81% | 42.24 | 10.96% |
Fidelity International Ltd
Goldentree Asset Management LP
Maple Rock Capital Partners, Inc.
ICAHN CARL C
River Road Asset Management, LLC
Alberta Investment Management Corp
bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Organization | Bausch + Lomb Corp. |
Employees | 13300 |
CEO | Mr. Osama A. Eldessouky |
Industry | Healthcare |